Abstract-Sphingosine-1 phosphate (S1P) is a bioactive sphingolipid that is critical in the development of blood vessels, and in the adult regulates vascular functions including vascular tone, endothelial integrity, and angiogenesis. Further, S1P may regulate arterial lesions in disease and after injury by controlling leukocyte recruitment and smooth muscle cell functions. I n this brief review we have concentrated on the role of sphingosine-1 phosphate (S1P) with respect to vascular functions. For information on sphingolipid metabolism and the role of S1P on the immune system, the nervous system, and cancer, the reader might refer to several excellent reviews. [1] [2] [3] [4] [5] [6] 
S1P Levels
S1P is generated from sphingomyelin, an integral component of plasma membranes, by the sequential action of sphingomyelinase, ceramidase, and sphingosine kinase (SphK). Degradation of S1P occurs by dephosphorylation or cleavage by S1P-lyase. Currently 2 SphKs, 2 S1P-phosphatases, and 1 S1P-lyase have been identified. [12] [13] [14] [15] The 2 SphKs exhibit different expression patterns and kinetic properties and may therefore regulate different S1P-dependent processes. 16 But they also have redundant functions as the double knockout is lethal, whereas mice lacking either SphK1 or SphK2 are phenotypically normal. 17, 18 Regulation of SphK activities occurs by multiple mechanisms including transcriptional activation, reversible phosphorylation, and interaction with other proteins. 16 Once synthesized, S1P can be secreted from cells, and in platelets and mast cells, S1P export across the cell membrane is mediated by members of the ATP-binding cassette (ABC) family of transporters. 19, 20 In vivo, a steep concentration gradient exists for S1P. It is present at nanomolar concentrations in tissues but at micromolar concentrations in plasma. This gradient regulates lymphocyte egress from lymphatic organs, and inhibition of S1P1R blocks this event. 3 The dissociation constants for S1PRs are in the 2 to 20 nmol/L range, and so potentially vascular cells are exposed to saturating concentrations of S1P. 21 Plasma S1P, however, is protein-bound and may not be accessible for receptor binding. Approximately 60% of plasma S1P is found in the lipoprotein fraction where it is bound mainly to HDL, and the remaining 40% is bound to albumin. 22, 23 Many cell types potentially regulate plasma S1P levels, including platelets and erythrocytes that both lack S1P degrading enzymes. 24, 25 Endothelial cells have recently been shown to release S1P in response to laminar shear stress. 26 To what extent plasma levels of S1P regulate vascular homeostasis is unclear. With respect to a role for S1P after vascular injury, one must consider that S1P might also be generated locally, although this remains to be demonstrated. We have found an increase in SphK1 expression after arterial injury (data not shown), and others have observed activation of SphK1 on lung injury and ischemia-reperfusion injury of the heart. In both models, S1P decreased the extent of injury. 27, 28 
Role of S1PRs in Vascular Development
The most significant data thus far as to the role for S1P in vascular development are from studies using S1PR knockout mice. Deletion of S1P1R in mice is embryonic lethal because of massive hemorrhaging, caused by a defect in recruiting mural cells to the endothelial tubes. 29, 30 A tissue-specific deletion of S1P1R in the endothelium produced the same phenotype demonstrating that endothelial S1P1R is required for vessel coverage during development. 30 When deleted individually, the S1P2R-and S1P3R-null mice have no severe phenotype; the double-null mice, however, are born with less than the expected frequency. 10, 31 These mice have abnormally thin endothelial cells, and their vessels are prone to rupture. 31 Recently S1P2R-null mice were found to be deaf because of damage and loss of sensory hairs in the auditory canal. 32, 33 The basis for this malformation appears to lie within the stria vascularis, where the vasculature is highly dilated. One consideration is that S1P2R is necessary for S1P-induced vasoconstriction which normally protects capillaries against high blood pressure. 33 In part, this conclusion is supported by the finding that mesenteric and renal arteries in S1P2R-null mice exhibit decreased resistance especially after phenylephrine-induced vasoconstriction. 34 
Regulation of Vascular Tone by S1P
S1P can both contract and relax arteries ( Figure 1 ). 35, 36 In rats, S1P constricts small resistance arteries such as mesenteric as well as cerebral and renal arteries but has no effect on the aorta or carotid or femoral arteries. [37] [38] [39] [40] In contrast, S1P dilates rat aortic rings that have been preconstricted with phenylephrine (PE). 41, 42 This is thought to be regulated via S1P3R-dependent activation of eNOS and NO production by endothelial cells. [41] [42] [43] In part, the different responses to S1P may be explained by the variable expression of S1PRs in arteries. For example, in rats, protein expression of S1P2R and S1P3R is 4-fold higher in cerebral arteries compared to the aorta, 44 and gracilis muscle resistance arteries in hamsters express message for S1P2R but not for S1P3R. 45 Studies using S1PR-null fibroblasts indicate that S1P3R regulates contraction by promoting calcium mobilization from intracellular stores, whereas S1P2R increases calcium sensitivity by RhoA/Rho kinase-dependent phosphorylation and inhibition of myosin light chain phosphatase. 10, 46 This would suggest that S1P3R is critical for S1P-induced arterial constriction, however this fact is at odds with the observation that activation of S1P3R is important for eNOS-regulated vasodilation of arteries. 43 Another report shows that loss of S1P2R results in a decrease of vascular tone and blunting of the contractile response in mesenteric arteries to PE. 34 An important issue in these studies is that S1P2R-null arteries were stimulated with PE in the absence of exogenous S1P. How, therefore, is loss of S1P2R regulating tone? One suggestion is that endogenous S1P synthesized by the arterial wall regulates tone through S1P2R. 36 This idea is consistent with studies showing that overexpression of SphK1 increases tone in resistance arteries, while this action is antagonized by overexpression of sphingosine phosphatase-1. 45, 46 
S1P and Endothelial Function
Both S1P1R and S1P3R are important for the regulation of angiogenesis in the adult, and the addition of S1P to endothelial cells stimulates their proliferation, migration, shape change, and survival 47, 48 (Figure 1 ). Consistent with a role for S1P in angiogenesis is the observation that downregulation of S1PRs with the synthetic S1P analogue, FTY720 (fingolimod), attenuates angiogenesis and tumor growth. 49 FTY720 has a similar structure to sphingosine and is phosphorylated in vivo. Once phosphorylated, it binds and activates S1P1R and S1P3R but not S1P2R. In the long term, it causes internalization and degradation of S1P1R in lymphocytes, and in this way, acts as a functional antagonist. 4 Consistent with its role in angiogenesis, daily infusions of S1P increase blood flow in a mouse model of hind limb ischemia. 50 In this study the rate of blood flow recovery is too fast to be attributed simply to angiogenesis and in all probability arteriogenesis, lumen expansion of small collateral vessels, is important. 50 S1P promotes endothelial barrier function by upregulating adhesion molecules such as VE-cadherins (Figure 1 ). [51] [52] [53] For example, the activity of VEGF, which promotes endothelial growth and decreases vascular permeability, is inhibited by FTY720. It is well known that platelets are required for vascular integrity, 54, 55 and it is interesting to speculate that platelet-derived S1P plays a role in this process.
S1P and Atherosclerosis
The role of S1P in atherosclerosis is complex as it has both pro-and antiatherosclerotic properties (Figure 2) . A single clinical report in man shows that serum S1P was more predictive of obstructive coronary heart disease than traditional risk factors, 56 which indicates the possibility that S1P is a biomarker for this disorder. Treatment of LDLR-null as SMCs express S1P1R, S1P2R and S1P3R. S1P2R and S1P3R may regulate the vascular tone depending on the vascular bed.
Endothelial cells express S1P1R and S1P3R. S1P regulates endothelial integrity and angiogenesis in the adult.
Figure 1. Role for S1PRs in normal arteries.
Lymphocytes: S1P1R is required for egress of lymphocytes from lymphatic organs.
Macrophages: S1P may regulate macrophage content in lesions and control the ratio between inflammatory M1-and anti-inflammatory M2 macrophages.
Endothelial cells: S1P1R inhibits monocyte/endothelial cell/cell interaction. S1P3R may regulate expression of adhesion molecules. S1P induces NO production in S1P3R-dependent manner. well as ApoE-null mice with FTY720 significantly reduces atherosclerotic lesions and the number of lymphocytes present in lesions. 57, 58 This is likely attributable to FTY720-mediated downregulation of S1P1R on lymphocytes. In ApoE-null mice, 20 weeks of FTY720 treatment also decreased the number of arterial macrophages, and the authors suggested that the drug stimulates S1P3R-mediated NO-production thus inhibiting the release of the monocyte chemokine MCP-1 by SMCs. 58 In FTY720-treated LDLR-null mice, proinflammatory cytokines were reduced, and the ratio between inflammatory M1-and antiinflammatory M2-macrophages was decreased. 57 Further, S1P may also regulate leukocyte or monocyte numbers in lesions by regulating the expression of endothelial adhesion molecules. Confusingly, both activation and inhibition of this process by S1P have been described. 59 -62 These contradictory observations may be attributable to differences in S1PR expression in the endothelial cells used or to the possibility that different S1P concentrations were used in these experiments. As mentioned above, about 50% of plasma S1P is bound to HDL, and that fraction of S1P may play an important role in attenuating atherosclerosis by mediating antiatherogenic effects of HDL including activation of eNOS. 41 NO derived by eNOS activity is a potent antiatherogenic compound as has been demonstrated by manipulating eNOS expression in mice 63 and rabbits. 64 In conclusion, whether S1P promotes or inhibits atherosclerosis is debatable. 65, 66 Effects of S1P may significantly differ depending on its source (plasma or locally produced), its concentration, the nature of its binding protein, and the pattern of S1PR expression by vascular cells.
S1P and Arterial Stenosis
The role of S1P and vascular stenosis has recently been explored because of the availability of S1PR-null mice and specific S1PR antagonists ( Figure 3 ). As mentioned above, S1P1R deletion is lethal, 29, 30 and consequently, the specific role of this receptor in stenosis will await the investigation in tissue-specific knockout mice. In our laboratory, S1P2R-null mice were subjected to carotid artery ligation, and after 28 days a significantly larger neointimal lesion developed as compared to wild-type arteries. 67 The growth of these lesions was accompanied by high and sustained increase in SMC replication. 67 Interestingly, we have been unable to document that S1P2R-null SMCs in vitro have a higher rate of proliferation, but these cells migrate faster than wild-type cells which might explain the larger lesions in injured S1P2R-null arteries. 67 This assumption is consistent with previous observations in vitro that S1P inhibits migration in adult SMCs in a S1P2R-dependent manner. 68, 69 Once established in the neointima SMCs undergo rapid replication, which might be not linked to S1P2R expression. Indeed, we have consistently found that both in injured rat and mice arteries, intimal SMCs maintain a rapid increase in replication with the first 7 to 10 days after injury by an as yet unknown mechanism. 70 -72 Another possible explanation as to how S1P2R might suppress neointimal formation is that S1P2R promotes SMC differentiation, thereby limiting the growth potential of SMCs. In vitro, induction of smooth muscle actin (SMA) and other differentiation genes by S1P has been reported, 73 and we have observed that SMA expression is much lower in the carotid arteries of S1P2R-null mouse compared to littermate controls after injury (unpublished data). Activation of RhoA by S1P largely depends on S1P2R, and by this mechanism myocardin-related transcription factors may translocate from the cytosol into the nucleus where they cooperate with serum-response factor to promote expression of SMC differentiation genes. 74, 75 A positive role for S1P in neointimal growth has been indicated by a study carried out in ballooned rat carotid arteries, in which a S1P1R/S1P3R antagonist, VPC44116, decreased neointimal lesions by 50%. 76 The arterial injury induced a rapid but transient increase in S1P1R and S1P3R, but at later times an increase in S1P2R was observed. 76 Given that both S1P1R and S1P3R stimulate SMC migration in vitro, this pattern of early expression of S1PRs regulating migration followed by later expression of S1P2R, which inhibits SMC migration, fits well with the development of intimal lesions. 68, 69 We have recently found that 28 days after loop injury, the neointima in injured mice S1P3R-null iliac arteries is significantly smaller than in wild-type littermates (unpublished data). How S1P3R promotes neointimal growth is unknown, but stimulation of migration is suggested for its ability to activate Rac1. 77 Given that different arteries express a different mix of S1PRs, 44, 45 it is an intriguing possibility that arteries with high expression of S1P3R compared to S1P2R are more susceptible to intimal growth after injury.
A final issue with respect vascular hyperplasia is that S1PRs cross-talk to other receptors and so regulate different signaling pathways that might control SMC functions. S1P transactivates platelet-derived growth factor-␤ (PDGFR␤) and epidermal growth factor receptor in SMCs via activation of a G␣i-coupled S1PR; both these receptor tyrosine kinase receptors are known to regulate SMC proliferation and migration. 78, 79 Conversely, PDGFR␤ can indirectly transactivate S1PRs through enhanced expression of SphK1, and thus, S1P signaling may modulate PDGF activities. 80, 81 
Conclusion
There are significant data now linking S1P to vascular functions, but the precise mechanisms involved require further clarification. Open questions are how does the nature of the S1P binding protein regulate S1PR signaling, and how important is locally produced S1P versus plasma-derived S1P. Other issues, only just now being examined, are the importance of differences in S1PR expression in various vascular beds and their regulation in disease or after injury.
SMCs: S1P1R and S1P3R may stimulate migration and proliferation. S1P2R may inhibit migration and promote SMC differentiation.
Endothelial cells: A role for S1PRs in the growth of arterial lesions has not been indicated so far. 
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